Stock Taper
SCREENER COMPARE ANY 2 STOCKS
LGND
LIGAND PHARMACEUTICALS INCORPORATED
NASDAQ
$280.49
▼ DOWN 1.42% (-4.03)

KEY STATISTICS

Market Cap$5.62 B
52w High$326.63
52w Low$160.80
Dividend Yield5.35%
FrequencySpecial
P/E30.79
Volume127.69K
Shares Out.20.04M

COMPANY

LEADERSHIP

Todd C. Davis
CHIEF EXECUTIVE
Todd C. Davis

COMPENSATION 2026

Salary$695,834
Stock Awards$6,429,536
Incentive Plan Pay$637,000
All Other Comp.$9,960
Total$12,914,980

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 18, 1992
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
47

PRICE TARGET

Target High$358.00
Target Low$326.00
Target Median$336.00
Target Consensus$338.50

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$78.09M
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2022-11-02Forward1603:1000
2010-11-19Reverse1:6

PRICE

$280.49 ▼ DOWN 1.42% (−$4.03)
OVERLAYS
$278$280$282$2849:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM280.49

About Ligand Pharmaceuticals Incorporated

https://www.ligand.com ↗

Ligand Pharmaceuticals develops technologies and commercial products across various therapeutic areas, including cancer, COVID-19, osteoporosis, and infectious diseases, while licensing and selling drug formulations and materials globally.

INDUSTRY

Biotechnology

A PRODUCT LIGAND PHARMACEUTICALS INCORPORATED IS KNOWN FOR

ZELSUVMI™ (berdazimer gel, 10.3%)
ZELSUVMI™ (berdazimer gel, 10.3%)

ZELSUVMI is the first FDA-approved at-home prescription topical treatment for molluscum contagiosum, offering a convenient, FDA-approved option for children, with commercial launch in 2024.

COMPETITORS

COMPETITOR
ARQT COMPARE
MANE COMPARE
SLGL COMPARE
VRCA COMPARE

Revenue by Products

IconPRODUCTQ2-2025Q3-2025Q4-2025Q2-2026
Royalty$36.4M $46.59M ▲$50.53M ▲$48.03M ▼
Intangible Royalty Assets$30.08M $40.16M ▲$40.7M ▲$37.36M ▼
Financial Royalty Assets$6.31M $6.42M ▲$9.83M ▲$10.67M ▲
Material Sales Captisol$8.29M $10.67M ▲— $7.98M ▼
Kyprolis$8.8M $11.62M ▲— $7.04M ▼
Rylaze$2.86M $3.56M ▲— $3.2M ▼
Contract Revenue— $131K $66.74M ▲$2.68M ▼
Evomela$1.47M $1.89M ▲— —
Teriparatide Injection$2.3M $2.63M ▲— $1.47M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
227
LISTED HERE
26
RANKED BY POSITION SIZE
XSMC.TO
0.31% · 1.2M
VTI
0.01% · 608.0K
XSMO
1.89% · 201.5K
SPSM
0.31% · 188.4K
SCHA
0.12% · 95.2K
DFMC
0.28% · 77.5K
FPX
0.82% · 43.6K
CSMD
2.51% · 42.8K
PSC
0.30% · 29.8K
USVM
0.40% · 25.2K
XRSU.L
0.18% · 18.2K
JMEE
0.16% · 16.6K
FSMD
0.15% · 13.8K
GSC
1.24% · 12.3K
RSSL
0.18% · 9.6K
JSML
0.60% · 7.8K
BBP
1.37% · 5.7K
JHSC
0.21% · 5.3K
AI
AIMS
1.52% · 4.8K
HELX
4.16% · 4.8K
TPSC
0.29% · 4.0K
NBSM
0.92% · 3.8K
EZM
0.11% · 3.6K
BIOT.L
3.19% · 2.7K
BFOR
0.31% · 2.6K
ALIL
2.56% · 2.3K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
595
TOP 12 OF 595 · RANKED BY POSITION SIZE
Tudor Investment Corp Et Al
15.8M sh · $17.7M
Blackrock, Inc.
3.1M sh · $980.19M
Blackrock Inc.
2.9M sh · $241.95M
Vanguard Group Inc
2.1M sh · $367.79M
Blackrock Fund Advisors
1.8M sh · $180.13M
Invesco Ltd.
1.2M sh · $379.83M
Janus Henderson Group Plc
1.0M sh · $184.65M
State Street Corp
826.5K sh · $261.25M
Rs Investment Management Co LLC
824.8K sh · $98.37M
Fmr LLC
762.8K sh · $241.12M
Franklin Resources Inc
752.0K sh · $237.71M
Macquarie Group Ltd
751.8K sh · $133.17M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity5
Return On Assets5
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score3

TRADES BY CONGRESS

HOUSE TRADES
Gilbert Cisneros
Gilbert Cisneros
Purchase
2026-05-29
 Katherine M. Clark
Katherine M. Clark
Sale (Full)
2020-10-22

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
Espinoza Octavio
Sale · 31.6K shares
2026-08-12
★
OFFICER: CHIEF FINANCIAL OFFICER
Espinoza Octavio
Sale · 2.9K shares
2026-08-12
★
DIRECTOR
Haas Jason
Sale · 7.1K shares
2026-08-12
★
OFFICER: CHIEF FINANCIAL OFFICER
Espinoza Octavio
Sale · 7.2K shares
2026-08-12

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
OUTPERFORM 2
7 GRADES IN THE LAST 12 MONTHS
RBC Capital OUTPERFORM HC Wainwright & Co. BUY Oppenheimer OUTPERFORM B of A Securities BUY Stifel BUY Citigroup BUY Benchmark BUY

SECTORS PEERS

PEERPRICE
PRAX$344.75COMPARE
CRNX$84.84COMPARE
BLTE$151.72COMPARE
MIRM$97.46COMPARE
ACAD$29.11COMPARE
DYN$25.07COMPARE
VKTX$32.16COMPARE
NAMS$25.90COMPARE